Humulin S (Soluble) (Insulin Human)

Humulin S is indicated for the control of blood glucose in patients who require insulin replacement, including both type 1 and type 2 diabetes mellitus, as well as specific acute metabolic situations commonly.

• Initiation of insulin therapy in newly diagnosed type 1 diabetes.
• Supplemental insulin for type 2 diabetes patients inadequately controlled on oral agents.
• Adjustment of basal insulin during pregnancy (category B) under medical supervision.
• Adjunctive treatment of diabetic ketoacidosis when combined with intravenous insulin.
• Perioperative glucose management in surgical patients with diabetes.

• Humulin S contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the β‑subunit, initiating the PI3‑K/Akt signaling cascade. This cascade promotes translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, while simultaneously suppressing hepatic gluconeogenesis and glycogenolysis, thereby lowering circulating blood glucose levels. The net effect is a rapid reduction in plasma glucose within minutes after subcutaneous injection.

Adverse reactions to Humulin S may vary in frequency and severity; they are generally related to its pharmacologic action or formulation.

Common

• Mild hypoglycemia, characterized by sweating, tremor, or dizziness.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized fat loss or accumulation.
• Transient weight gain due to fluid retention.
• Transient visual disturbances such as blurred vision.
• Mild nausea or abdominal discomfort.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Hypersensitivity leading to eosinophilia or fever.
• Persistent edema or heart failure exacerbation.
• Insulin antibody formation that may alter drug efficacy.

When prescribing Humulin S, clinicians should evaluate patient-specific factors and monitor for conditions that could increase risk of adverse outcomes.

• Assess renal or hepatic impairment, as reduced clearance may prolong insulin action.
• Review history of hypoglycemia unawareness before initiating therapy.
• Adjust dose during pregnancy, lactation, or in elderly patients.
• Monitor for signs of infection or inflammation at injection sites.
• Caution in patients with cardiovascular disease or heart failure due to fluid retention risk.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Consider temporary dose reduction during periods of reduced food intake or increased physical activity.

Humulin S may interact with other medications or substances that affect glucose metabolism, insulin absorption, or cardiovascular status.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• High‑dose beta‑blockers that mask hypoglycemia symptoms.
• MAO‑inhibitors combined with sympathomimetic agents that can cause unpredictable glucose changes.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require insulin dose changes.
• Diuretics, especially thiazides, that can affect electrolyte balance and glucose control.
• Alcohol consumption, which can potentiate hypoglycemia after insulin administration.